Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of potassium citrate and allopurinol is used in the treatment of various conditions related to uric acid metabolism, particularly for managing kidney stones and hyperuricemia. This combination therapy works through complementary mechanisms - allopurinol reduces uric acid production while potassium citrate helps increase urinary pH and enhance uric acid excretion. ## Pharmacological Properties Allopurinol functions as a xanthine oxidase inhibitor, blocking the enzyme responsible for converting xanthine to uric acid, thereby reducing serum uric acid levels[6][7]. Potassium citrate acts as an alkalizer that increases urinary pH, which helps prevent the formation of uric acid stones and enhances uric acid excretion[4][10]. Studies have shown that when used in combination, these medications provide enhanced therapeutic benefits. Research indicates that adding potassium citrate to allopurinol therapy significantly reduces serum uric acid levels beyond what allopurinol achieves alone - with combination therapy showing a 16% reduction compared to only 6.8% with allopurinol monotherapy[4]. ## Clinical Applications This combination therapy is primarily used for: 1. **Management of gout and hyperuricemia** - The dual mechanism helps control uric acid levels more effectively than either medication alone[4]. 2. **Prevention and treatment of kidney stones** - Particularly effective for calcium oxalate stones and uric acid lithiasis[6][7][9]. 3. **Reducing uric acid levels during cancer treatment** - Helps prevent complications like tumor lysis syndrome during chemotherapy for leukemia and lymphoma[7]. ## Safety Profile No direct interactions between allopurinol and potassium citrate have been reported in the search results[1]. However, each medication has its own safety considerations: - Allopurinol may interact with ACE inhibitors, azathioprine, mercaptopurine, and certain other medications[5]. - Patients should be monitored for potential adverse events, though clinical studies showed minimal concerns with the combination therapy[4]. In one clinical study following patients for 33 months on combined treatment with prednisone, allopurinol, and potassium citrate, patients remained stone-free with normal urinary calcium, pH, and citrate levels[2]. ## Dosing Considerations Dosing varies based on the specific condition being treated and patient factors: - Allopurinol is typically administered at 100-300 mg daily, with adjustments for renal function[7][8]. - Potassium citrate dosing often ranges from 3-6 g daily[4][9]. For patients with reduced renal function, dosage adjustments may be necessary, particularly for allopurinol[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allopurinol and Potassium Citrate combination.